EE230 The Real-World Cost-Effectiveness of Faricimab Versus Existing and Future Biosimilars in Patients with Neovascular Age-Related Macular Degeneration in Canada
Abstract
Authors
Christian Bührer Oliver Cox Marloes Bagijn Demitri Diles Simon Yunger